Quality and Efficacy Concerns with Generics in Treatment of Hepatitis C with Directly Acting Antivirals
Treating hepatitis C has never been so convenient after the advent of Directly Acting Antivirals (DAA). Convenience is at both ends; for the doctors to prescribe and for patients to comply due to all oral therapy with few adverse effects. Many are already in market, these include, Sofosbuvir, Decla...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dow University of Health Sciences
2017-08-01
|
| Series: | Journal of the Dow University of Health Sciences |
| Online Access: | https://jduhs.com/index.php/jduhs/article/view/1381 |
| _version_ | 1797818414474985472 |
|---|---|
| author | Bader Faiyaz Zuberi |
| author_facet | Bader Faiyaz Zuberi |
| author_sort | Bader Faiyaz Zuberi |
| collection | DOAJ |
| description |
Treating hepatitis C has never been so convenient after the advent of Directly Acting Antivirals (DAA). Convenience is at both ends; for the doctors to prescribe and for patients to comply due to all oral therapy with few adverse effects. Many are already in market, these include, Sofosbuvir, Declastavir & Velpastavir while many others are in pipeline. The SVR success rates with
these newer drugs is approaching 99% and they are also showing improvement in fibrosis1,2. Cost of innovative brands of DAAs is very high. According to one study Quality-Adjusted Life Years (QALY) with innovator sofosbuvir for short therapy resulted in expense of $24,000 as compared to no treatment3 . Pakistan being a poor country with low per capita income, health and
innovator brand medicines are not in approach of average patient. With availability of generics there is up to 70%
reduction in cost of treatment and they come into the affordability range of most of the patients4-7
.
|
| first_indexed | 2024-03-13T09:07:35Z |
| format | Article |
| id | doaj.art-25371e7150784f6da3e069161f9f03ea |
| institution | Directory Open Access Journal |
| issn | 1995-2198 2410-2180 |
| language | English |
| last_indexed | 2024-03-13T09:07:35Z |
| publishDate | 2017-08-01 |
| publisher | Dow University of Health Sciences |
| record_format | Article |
| series | Journal of the Dow University of Health Sciences |
| spelling | doaj.art-25371e7150784f6da3e069161f9f03ea2023-05-28T03:10:05ZengDow University of Health SciencesJournal of the Dow University of Health Sciences1995-21982410-21802017-08-01112Quality and Efficacy Concerns with Generics in Treatment of Hepatitis C with Directly Acting AntiviralsBader Faiyaz Zuberi0DUHS Treating hepatitis C has never been so convenient after the advent of Directly Acting Antivirals (DAA). Convenience is at both ends; for the doctors to prescribe and for patients to comply due to all oral therapy with few adverse effects. Many are already in market, these include, Sofosbuvir, Declastavir & Velpastavir while many others are in pipeline. The SVR success rates with these newer drugs is approaching 99% and they are also showing improvement in fibrosis1,2. Cost of innovative brands of DAAs is very high. According to one study Quality-Adjusted Life Years (QALY) with innovator sofosbuvir for short therapy resulted in expense of $24,000 as compared to no treatment3 . Pakistan being a poor country with low per capita income, health and innovator brand medicines are not in approach of average patient. With availability of generics there is up to 70% reduction in cost of treatment and they come into the affordability range of most of the patients4-7 . https://jduhs.com/index.php/jduhs/article/view/1381 |
| spellingShingle | Bader Faiyaz Zuberi Quality and Efficacy Concerns with Generics in Treatment of Hepatitis C with Directly Acting Antivirals Journal of the Dow University of Health Sciences |
| title | Quality and Efficacy Concerns with Generics in Treatment of Hepatitis C with Directly Acting Antivirals |
| title_full | Quality and Efficacy Concerns with Generics in Treatment of Hepatitis C with Directly Acting Antivirals |
| title_fullStr | Quality and Efficacy Concerns with Generics in Treatment of Hepatitis C with Directly Acting Antivirals |
| title_full_unstemmed | Quality and Efficacy Concerns with Generics in Treatment of Hepatitis C with Directly Acting Antivirals |
| title_short | Quality and Efficacy Concerns with Generics in Treatment of Hepatitis C with Directly Acting Antivirals |
| title_sort | quality and efficacy concerns with generics in treatment of hepatitis c with directly acting antivirals |
| url | https://jduhs.com/index.php/jduhs/article/view/1381 |
| work_keys_str_mv | AT baderfaiyazzuberi qualityandefficacyconcernswithgenericsintreatmentofhepatitiscwithdirectlyactingantivirals |